Development and validation of a pathomics-driven machine learning model for individualized prediction of neoadjuvant chemotherapy response and early recurrence in HR-positive, HER2-negative breast cancer. - Yue J; Liu J; Kang X; Yuan P; Wang W; Wang Z; Shang C; Shang Q; Li G; Dong X; Wang T; Yang D; et al. (Frontiers in oncology, 2026)